Proteq West Nile


West Nile fever vaccine (live recombinant)

This medicine is authorised for use in the European Union.


Proteq West Nile is a veterinary vaccine that contains West Nile recombinant canarypox virus (vCP2017). It is available as a suspension for injection.

Proteq West Nile is used to protect horses from 5 months of age against West Nile disease. West Nile disease is a mosquito-borne viral disease that can cause encephalitis (inflammation of the brain) and meningitis (inflammation of the lining of the brain and spinal cord).The vaccine is used to reduce the number of horses with the West Nile virus in their blood (viraemia) or with clinical signs of the disease.

This EPAR was last updated on 15/02/2021

Authorisation details

Product details
Proteq West Nile
Agency product number
Active substance
West Nile recombinant canarypox virus (vCP2017 virus)
International non-proprietary name (INN) or common name
West Nile fever vaccine (live recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

55216 Ingelheim am Rhein

Product information

14/08/2020 Proteq West Nile - EMEA/V/C/002005 - IG/1279

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for equidae

  • Horse

Therapeutic indication

Active immunisation of horses from five months of age against West Nile disease by reducing the number of viraemic horses. If clinical signs are present, their duration and severity are reduced.

Assessment history

Related content

How useful was this page?

Add your rating